Sponsor pipeline

Grey Wolf Therapeutics clinical trial pipeline

Get alerts when Grey Wolf Therapeutics's trials change

2 active trials 2 recruiting 1 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days

2026-09-19
Primary endpoint(s) modified
NCT07047703 EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) · Phase 1/2

Active trials by phase

Phase 1/2
2

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1/2
NCT07047703 EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) Axial Spondyloarthritis (AxSpA) Recruiting 2026-09-18
NCT06923761 EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) Advanced Solid Malignancy Recruiting 2026-01-28

Disease areas by active trials

Ankylosing Spondylitis (1)

Get alerts when Grey Wolf Therapeutics's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free